As Ozempic, Mounjaro Grab Share, Can Metformin Get A Leg-Up From Long COVID?
US Prescription Data Show Big Gains For New Generation Drugs
Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help
You may also be interested in...
The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Company says its new API production facility in Denmark will come online in 2029 and help meet demand for pipeline products in serious chronic diseases. Novo is currently contending with supply crunches for its semaglutide products.